Literature DB >> 25660278

Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype.

Edward F McKone1, Priscilla Velentgas2, Anna J Swenson2, Christopher H Goss3.   

Abstract

BACKGROUND: The extent to which sweat chloride concentration predicts survival and clinical phenotype independently of CFTR genotype in cystic fibrosis is not well understood.
METHODS: We analyzed the US Cystic Fibrosis Foundation Patient Registry data using Cox regression to examine the relationship between sweat chloride concentration (<60, 60-<80, ≥80mmol/L), CFTR genotype (high and lower risk for lung function decline), and survival and mixed linear regression to examine the relationship between sweat chloride, CFTR genotype, and measures of lung function and growth.
RESULTS: When included in the same model, CFTR genotype, but not sweat chloride, was independently associated with survival and with lung function, height, and BMI. Among patients with unclassified CFTR genotype, sweat chloride was an independent predictor of survival (<60 HR 0.53 [0.37, 0.77], 60-<80 0.51 [0.42, 0.63]).
CONCLUSIONS: Sweat chloride concentration may be a useful predictor of mortality and clinical phenotype when CFTR genotype functional class is unclassified.
Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Genetics; Respiratory function; Survival analysis

Mesh:

Substances:

Year:  2015        PMID: 25660278     DOI: 10.1016/j.jcf.2015.01.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

1.  The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies.

Authors:  Anna Diana; Angela Maria Polizzi; Teresa Santostasi; Luigi Ratclif; Maria Giuseppina Pantaleo; Giuseppina Leonetti; Danila Rosa Iusco; Crescenzio Gallo; Massimo Conese; Antonio Manca
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

2.  Interventions for promoting participation in shared decision-making for children and adolescents with cystic fibrosis.

Authors:  Helen Malone; Susan Biggar; Sheila Javadpour; Zai Edworthy; Greg Sheaf; Imelda Coyne
Journal:  Cochrane Database Syst Rev       Date:  2019-05-23

3.  Quality of sweat test (ST) based on the proportion of sweat sodium (Na) and sweat chloride (Cl) as diagnostic parameter of cystic fibrosis: are we on the right way?

Authors:  Alethéa Guimarães Faria; Fernando Augusto Lima Marson; Carla Cristina de Souza Gomez; Maria Ângela Gonçalves de Oliveira Ribeiro; Lucas Brioschi Morais; Maria de Fátima Servidoni; Carmen Sílvia Bertuzzo; Eulália Sakano; Maura Goto; Ilma Aparecida Paschoal; Mônica Corso Pereira; Gabriel Hessel; Carlos Emílio Levy; Adyléia Aparecida Dalbo Contrera Toro; Andressa Oliveira Peixoto; Maria Cristina Ribeiro Simões; Elizete Aparecida Lomazi; Roberto José Negrão Nogueira; Antônio Fernando Ribeiro; José Dirceu Ribeiro
Journal:  Diagn Pathol       Date:  2016-10-26       Impact factor: 2.644

4.  How are the ancient cystic fibrosis patients? Cystic fibrosis diagnosed over 60 years-old.

Authors:  C Prados; M Lerín; J J Cabanillas; L Gómez-Carrera; R Álvarez-Sala
Journal:  Respir Med Case Rep       Date:  2017-03-24

5.  Standardized clinical criteria and sweat test combined as a tool to diagnose Cystic Fibrosis.

Authors:  Fabricio González-Andrade
Journal:  Heliyon       Date:  2018-12-17

6.  Unraveling the CFTR Function-Phenotype Connection for Precision Treatment in Cystic Fibrosis.

Authors:  Edith T Zemanick; Deepika Polineni
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

7.  Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?

Authors:  Katharina Niedermayr; Verena Gasser; Claudia Rueckes-Nilges; Dorothea Appelt; Johannes Eder; Teresa Fuchs; Lutz Naehrlich; Helmut Ellemunter
Journal:  Ther Adv Chronic Dis       Date:  2022-08-05       Impact factor: 4.970

8.  Sweat chloride assay by inductively coupled plasma mass spectrometry: a confirmation test for cystic fibrosis diagnosis.

Authors:  Antonella Marvelli; Beatrice Campi; Gianfranco Mergni; Maria Elisa Di Cicco; Paola Turini; Paolo Scardina; Riccardo Zucchi; Massimo Pifferi; Giovanni Taccetti; Aldo Paolicchi; Giancarlo la Marca; Alessandro Saba
Journal:  Anal Bioanal Chem       Date:  2020-07-21       Impact factor: 4.142

9.  Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.

Authors:  Danya Muilwijk; Marlou Bierlaagh; Peter van Mourik; Jasmijn Kraaijkamp; Renske van der Meer; Rutger van den Bor; Harry Heijerman; René Eijkemans; Jeffrey Beekman; Kors van der Ent
Journal:  J Pers Med       Date:  2021-12-16

10.  A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.

Authors:  Edith T Zemanick; Jennifer L Taylor-Cousar; Jane Davies; Ronald L Gibson; Marcus A Mall; Edward F McKone; Paul McNally; Bonnie W Ramsey; Jonathan H Rayment; Steven M Rowe; Elizabeth Tullis; Neil Ahluwalia; Chenghao Chu; Thang Ho; Samuel M Moskowitz; Sabrina Noel; Simon Tian; David Waltz; Tanya G Weinstock; Fengjuan Xuan; Claire E Wainwright; Susanna A McColley
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 21.405

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.